Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BIOQNASDAQ:CBLINASDAQ:ELOX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIOQBioqual$44.25$47.23$44.25▼$72.50$39.58M-0.1112 shsN/ACBLICleveland BioLabs$3.19$1.62▼$10.97$5K0.7271,922 shs115 shsELOXEloxx Pharmaceuticals$0.11$0.00▼$0.84N/A-1536.271,618 shs6 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIOQBioqual0.00%0.00%-1.67%-20.98%-38.97%CBLICleveland BioLabs0.00%0.00%0.00%0.00%-50.00%ELOXEloxx Pharmaceuticals0.00%0.00%0.00%0.00%-99.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIOQBioqualN/AN/AN/AN/AN/AN/AN/AN/ACBLICleveland BioLabsN/AN/AN/AN/AN/AN/AN/AN/AELOXEloxx PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIOQBioqual 0.00N/AN/AN/ACBLICleveland BioLabs 0.00N/AN/AN/AELOXEloxx Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIOQBioqual$58.59M0.67N/AN/AN/A∞CBLICleveland BioLabs$260K0.00N/AN/A$0.87 per share0.00ELOXEloxx PharmaceuticalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIOQBioqual$480K-$2.39N/A∞N/A-4.34%-5.82%-3.79%N/ACBLICleveland BioLabs-$2.40MN/A0.00N/AN/AN/A-32.84%-31.29%N/AELOXEloxx Pharmaceuticals-$36.06MN/A0.00N/AN/AN/AN/AN/AN/ALatest BIOQ, CBLI, and ELOX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/11/2025Q3 2025BIOQBioqualN/A$1.05N/A$1.05N/A$14.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIOQBioqual$0.501.13%N/AN/A N/ACBLICleveland BioLabsN/AN/AN/AN/AN/AELOXEloxx PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIOQBioqualN/A5.085.08CBLICleveland BioLabsN/A45.9345.93ELOXEloxx PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIOQBioqualN/ACBLICleveland BioLabs5.09%ELOXEloxx Pharmaceuticals2.90%Insider OwnershipCompanyInsider OwnershipBIOQBioqual39.24%CBLICleveland BioLabs1.03%ELOXEloxx Pharmaceuticals20.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIOQBioqual114890,000543,000Not OptionableCBLICleveland BioLabs415.48 millionN/ANot OptionableELOXEloxx Pharmaceuticals303.14 million2.51 millionNot OptionableBIOQ, CBLI, and ELOX HeadlinesRecent News About These CompaniesEloxx Pharmaceuticals Announces Key Corporate AccomplishmentsNovember 12, 2024 | tmcnet.comEloxx Pharmaceuticals (OTC:ELOX) Stock, Insider Trading ActivityOctober 6, 2024 | benzinga.comEloxx Pharmaceuticals Provides Pipeline and Financing UpdatesJuly 11, 2024 | globenewswire.comEloxx Pharmaceuticals Inc (ELOX)April 24, 2024 | investing.comDelveInsight Business Research, LLP: Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsightApril 17, 2024 | finanznachrichten.deAlport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsightApril 17, 2024 | finance.yahoo.comEloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program UpdatesApril 16, 2024 | globenewswire.comProposed Changes to BenevolentAI’s Board CompositionApril 15, 2024 | dutchnews.nlDScientists discover potential treatment approaches for polycystic kidney diseaseApril 6, 2024 | pharmabiz.comPNIH Reports Scientists Discover Potential Treatment Approaches for Polycystic Kidney DiseaseApril 5, 2024 | goldrushcam.comGGene therapy and glycoside drugs offer new hope for polycystic kidney disease treatmentApril 5, 2024 | msn.comNasdaq Inc. Buy Rating: EPS Growth, Valuation Expansion, and Strong FinTech ProspectsMarch 26, 2024 | markets.businessinsider.comAlmirall, S.A.: Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological DiseasesMarch 13, 2024 | finanznachrichten.deAlmirall gains rights to Eloxx’s rare dermatological disease asset in deal worth over $470mMarch 13, 2024 | pmlive.comPAlmirall signs yes-nonsense skin disease deal with Eloxx for $3M upfrontMarch 13, 2024 | fiercebiotech.comFAlmirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseasesMarch 13, 2024 | globenewswire.comAlmirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological DiseasesMarch 13, 2024 | businesswire.comEloxx Pharmaceuticals Stock (OTC:ELOX), Short Interest ReportFebruary 22, 2024 | benzinga.comVertex Pharmaceuticals Inc.February 16, 2024 | barrons.comEloxx Pharmaceuticals, Inc. (ELOX)February 6, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeBIOQ, CBLI, and ELOX Company DescriptionsBioqual OTCMKTS:BIOQ$44.25 0.00 (0.00%) As of 06/27/2025Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.Cleveland BioLabs NASDAQ:CBLICytocom, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule immunotherapies. Its product applies to autoimmune, inflammatory, infectious diseases and cancers. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.Eloxx Pharmaceuticals NASDAQ:ELOXEloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
